UGT1A1 polymorphisms as a pharmacogenetic markers for prediction of irinotecan-induced toxicities in metastatic colorectal cancer

X Liu, D Cheng, Q Kuang, G Liu, W Xu, None, Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians Pharmacogenomics Journal. ,vol. 14, pp. 120- 129 ,(2014) , 10.1038/TPJ.2013.10

M M Dias, J-P Pignon, C S Karapetis, V Boige, B Glimelius, D M Kweekel, P N Lara, P Laurent-Puig, E Martinez-Balibrea, D Páez, C J A Punt, M W Redman, G Toffoli, M Wadelius, R A McKinnon, M J Sorich, The effect of the UGT1A1∗28 allele on survival after irinotecan-based chemotherapy: A collaborative meta-analysis Pharmacogenomics Journal. ,vol. 14, pp. 424- 431 ,(2014) , 10.1038/TPJ.2014.16

Fotios Loupakis, Chiara Cremolini, Gianluca Masi, Sara Lonardi, Vittorina Zagonel, Lisa Salvatore, Enrico Cortesi, Gianluca Tomasello, Monica Ronzoni, Rosella Spadi, Alberto Zaniboni, Giuseppe Tonini, Angela Buonadonna, Domenico Amoroso, Silvana Chiara, Chiara Carlomagno, Corrado Boni, Giacomo Allegrini, Luca Boni, Alfredo Falcone, Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer The New England Journal of Medicine. ,vol. 371, pp. 1609- 1618 ,(2014) , 10.1056/NEJMOA1403108

Zhe-Yi Hu, Qi Yu, Qi Pei, Cheng Guo, Dose-Dependent Association between UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Low Doses Also Increase Risk Clinical Cancer Research. ,vol. 16, pp. 3832- 3842 ,(2010) , 10.1158/1078-0432.CCR-10-1122

D. Hall, G. Ybazeta, G. Destro-Bisol, M. L. Petzl-Erler, A. Di Rienzo, Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates. Pharmacogenetics. ,vol. 9, pp. 591- 606 ,(1999) , 10.1097/00008571-199910000-00006

E Marcuello, D Páez, L Paré, J Salazar, A Sebio, E del Rio, M Baiget, A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer. British Journal of Cancer. ,vol. 105, pp. 53- 57 ,(2011) , 10.1038/BJC.2011.206

Yi-Jing Chen, Fei Hu, Chun-Yan Li, Jue-Min Fang, Li Chu, Xi Zhang, Qing Xu, The association of UGT1A1*6 and UGT1A1*28 with irinotecan-induced neutropenia in Asians: a meta-analysis. Biomarkers. ,vol. 19, pp. 56- 62 ,(2014) , 10.3109/1354750X.2013.867534

Fei-fei Han, Chang-long Guo, Dan Yu, Jin Zhu, Li-li Gong, Guang-run Li, Ya-li Lv, He Liu, Guang-yu An, Li-hong Liu, Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan‑induced neutropenia in Asian cancer patients Cancer Chemotherapy and Pharmacology. ,vol. 73, pp. 779- 788 ,(2014) , 10.1007/S00280-014-2405-0

Masahide Onoue, Tomohiro Terada, Masahiko Kobayashi, Toshiya Katsura, Shigemi Matsumoto, Kazuhiro Yanagihara, Takafumi Nishimura, Masashi Kanai, Satoshi Teramukai, Akira Shimizu, Masanori Fukushima, Ken-ichi Inui, UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients International Journal of Clinical Oncology. ,vol. 14, pp. 136- 142 ,(2009) , 10.1007/S10147-008-0821-Z

Alfredo Falcone, Sergio Ricci, Isa Brunetti, Elisabetta Pfanner, Giacomo Allegrini, Cecilia Barbara, Lucio Crinò, Giovanni Benedetti, Walter Evangelista, Laura Fanchini, Enrico Cortesi, Vincenzo Picone, Stefano Vitello, Silvana Chiara, Cristina Granetto, Gianfranco Porcile, Luisa Fioretto, Cinzia Orlandini, Michele Andreuccetti, Gianluca Masi, Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest Journal of Clinical Oncology. ,vol. 25, pp. 1670- 1676 ,(2007) , 10.1200/JCO.2006.09.0928